The World Hypertension Market 2007-2023

Questions: Discounts, Updates etc.

Pages: 194

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £6999

Publication Date: 2007-09-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The market for hypertensives - led by the angiotensin II antagonists - is one of the largest and most profitable in the global pharmaceutical market, with total anti-hypertensive sales of $36600m in 2006. Hypertension, or high blood pressure, is a worldwide epidemic: by 2025 visiongain predict that worldwide there will be more than 1.5 billion sufferers of this disease. Modern lifestyles, such as poor diet and lack of exercise, are the main contributory factors to elevated blood pressure. Consequently, the incidence and prevalence of hypertension are increasing rapidly in both developed and developing countries.

This is a market the drug development sector cannot afford to ignore. Are new, potentially successful drugs going to change the market within the next 10 to 15 years? This report will tell you.

The World Hypertension Market 2007-2023 concentrates on the following essential aspects of the market:

The World Hypertension Market 2007-2023 examines the market for antihypertensive drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:

The hypertension market is one of the largest in the global pharmaceutical industry, with continued prospects for high revenue generation and market growth. Nevertheless, the hypertension market is facing great challenges in terms of strong internal competition and patent expiration with a concomitant generic threat. Clearly, there are also unmet needs in this market that require urgent attention. While the angiotensin II antagonists have provided an improved balance of efficacy and tolerability in recent years, it is possible that even newer classes of antihypertensive - such as the renin inhibitors - will also provide great therapeutic and commercial scope. Given the great challenges of treating hypertension, continued investment into the development of improved treatments is required, as well as basic scientific research into the disorder. Recent developments in both the pharmaceutical industry and the public sector provide scope for optimism.

Table of Contents

1. Executive Summary - Hypertension is a Serious Cause of Mortality Worldwide
2. Introduction to Hypertension
2.1 An Overview of Hypertension
2.2 Symptoms of Hypertension and Diagnosis of the Condition
2.3 Causes of Hypertension
2.4 Primary Hypertension
2.5 Secondary Hypertension
2.6 Pulmonary Hypertension
2.7 Epidemiology of Hypertension
2.8 Links with Other Disorders
2.9 The Treatment of Hypertension
2.9.1 Countering Hypertension Through Changes in Diet and Lifestyle - A First Line of Attack
2.9.2 Treatment Targets and the Selection of Drugs
2.9.3 Beta Blockers
2.9.4 Angiotensin Converting Enzyme (ACE) Inhibitors
2.9.5 Calcium-Channel Blockers
2.9.6 Angiotensin II Blockers
2.9.7 Alpha Blockers
2.9.8 Diuretics
2.9.9 Tekturna/Rasilez (aliskiren) - a First-In-Class Renin Inhibitor 2.9.10 Other Drugs 2.10 The Treatment of Pulmonary Hypertension
2.11 The Prospects for Patients
3 The World Hypertension Market, 2007-2023
3.1 Growing Demand and Shifting Internal Dynamics in the World Anti-hypertensive Market, 2007-2023
3.2 Novartis to Become the Leading Company in the Hypertension Market by the End of the Decade
3.3 Angiotensin II Blockers to Continue Their Domination of the Anti-hypertensive Market, 2006 Onwards
3.4 Other Classes of Anti-hypertensive Drug Will Display High Revenues during 2006-2012
3.5 Calcium Channel Blockers - Declining Revenues due to Heightened Competition
3.6 Angiotensin Converting Enzyme (ACE) Inhibitors - Will This Class Be Superseded by the Angiotensin II Blockers?
3.7 Beta-Blockers - Carving a Secure Niche in a Highly Competitive Market?
3.8 Alpha Blockers Will Maintain a Respected Position in the Hypertension Market
3.9 Competition in the Anti-hypertensive Market to Become Increasingly Intense 3.10 Monotherapy or Combination Therapy?
3.11 Diuretic Agents Retain Importance
4. The World Market for Angiotensin II Blockers, 2007-2023
4.1 Angiotensin II Blockers - Strong Growth Leads to Continuing Predominance in the Market
4.1.1 The Angiotensin II Blockers Will Benefit From More Secure Patent Protection Than The Other Classes of Antihypertensives
4.1.2 Other Advantages of Angiotensin II Blockers That Confer Important Benefits in the Market
4.2 Diovan to Take Market Leadership from Norvasc by 2007
4.2.1 Diovan/Co-Diovan Benefits From High Prescription Rates in the US Market
4.2.2 Paediatric Exclusivity Granted by FDA in 2007
4.2.3 Approval for Reduction of Cardiovascular Death
4.2.4 Diovan Benefits from Further Clinical Studies
4.2.5 Recent Support from The European Society of Cardiology
4.2.6 The AVVANCE Trial Provided Further Support for Diovan
4.2.7 The NAVIGATOR Trial for Improved Glucose Tolerance
4.3 Cozaar/Hyzaar - High Revenues Followed by Decline
4.3.1 Development for Diabetic Nephropathy - The RENAAL study
4.3.2 FDA Approval for LVH
4.3.3 Diabetic Nephropathy Approval in Japan During 2006
4.3.4 Further Developments for Cozaar/Hyzaar
4.4 Avapro/Aprovel/Avalide to Maintain Steady Growth
4.4.1 Avaprovel/Avapro Benefits from Continuing Development
4.4.2 BMS Places High Emphasis on Irbesartan
4.4.3 Sublicensing of Irbesartan for Japanese Market
4.5 Blopress - Another Strong Performer
4.5.1 Additional FDA Approval for Blopress
4.6 Micardis Will Become a Leading Blockbuster by the End of the Decade
4.6.1 Micardis Shows Potential Metabolic Benefits
4.6.2 Micardis Benefits from Further Clinical Studies
4.6.3 Further Clinical Studies May Confer a Market Advantage to Micardis
4.7 Benicar/Olmetec’s Revenue Growth Set to Continue Steadily
4.7.1 Further Licensing Agreements for Benicar
4.7.2 Promising Results from Further Clinical Study
4.7.3 Sankyo Used Licensing Deals for International Marketing
4.7.4 The ORIENT Study and Other Developments
4.8 Exforge Will Achieve Blockbuster Revenues by The End of the Decade
4.9 Other Agents Will Have an Increasing Presence in the Angiotensin II Blockers Market
5 The World Market for Calcium Channel Blockers, 2006-2023
5.1 Increased Competition Will Lower Revenues Among the Calcium Channel Blockers
5.2 Norvasc - 2006 Hypertension Market Leader Set to Lose Dominance to Leading Angiotensin II Blockers
5.2.1 Norvasc is Going To Suffer from Prescribing Shift to Angiotensin II Antagonists
5.2.2 Norvasc Has Faced Serious Patent Challenges
5.2.3 Norvasc Benefits from Further Clinical Testing
5.2.4 Active Ingredient in Norvasc Combined with that of Lipitor to Form Dual Action Cardiovascular Drug
5.2.5 New Combination Product Exforge Will Draw Sales from Both Norvasc and Diovan
5.3 Lotrel Reaches Blockbuster Revenue Levels then Declines
5.3.1 Lotrel is a Prominent Combination Product
5.3.2 The ACCOMPLISH Study for High Risk Hypertension
5.4 Adelat Faces a Gradual Decline
5.4.1 Adelat is a Fine Example of Lifecycle Prolongation
5.5 Amlodin Follows the General Trend for Calcium Blockers
5.6 Other Agents Will Exert An Increasing Presence in the Calcium Blocker Market
6. The World Market for Beta-Blockers, 2006-2023
6.1 Beta Blockers Will Retain Their Niche Despite a Marked Decline in Sales
6.1.1 Uses and Limitations of Beta Blockers That Affect Their Position In The Market
6.2 Toprol-XL/Seloken Will Remain the Most Important Beta Blocker from 2007 Onwards
6.2.1 Approval for Cardiac Failure
6.2.2 Toprol-XL Faces Patent Challenges
6.3 Coreg Will Be The Second Largest Beta blocker from 2007 Onwards
6.3.1 Coreg Faces Increasing Generic Competition
6.3.2 Coreg May Benefit From Further Clinical Studies
6.3.3 Licensing of Carvedilol
6.4 Concor/Bisoprolol
6.4.1 Phase III Trials in Japan for Chronic Heart Failure
6.5 Other Agents Will Have an Increasing Presence in the Beta Blocker Market
7 The World Market for ACE Inhibitors, 2006-2023
7.1 How Well Will The ACE Inhibitors Resist Competition From The Angiotensin II Blockers?
7.1.1 ACE Inhibitors Will Retain Prominence in The Market
7.2 Delix/Tritace Will Retain Predominance in this Class
7.2.1 Licensing Agreements for International Distribution
7.2.2 Further Clinical Studies and Life Cycle Management to Confer Benefits to Delix/Tritace
7.3 Altace Will Maintain Second Place in the ACE inhibitor Market
7.4 Vasotec/Vaseretic - This Older Drug Will Face Decline
7.4.1 Enalapril is a Versatile ACE Inhibitor
7.4.2 Additional Clinical Studies and Product Development to Benefit Vasotec
7.5 Other Agents Will Have an Increasing Presence in the ACE inhibitors Market
8. The World Market for Alpha Blockers, 2006-2023
8.1 Alpha blockers Will Lose Prominence in the Hypertension Market
8.1.1 Alpha Blockers Are Also Used to Treat BPH
8.1.2 Limitations On The Use of Alpha Blockers Influence Their Performance in The Market
8.2 Cardura Will Dominate the Alpha Blocker Class
8.3 Other Agents Will Have an Increasing Presence in the Alpha blocker Market
9 The World Market for Other Hypertensive Agents, 2006-2023
9.1 Will New Antihypertensive Classes Such As the Renin Inhibitors Challenge the Established Agents?
9.2 Tracleer - a Blockbuster of the Future
9.2.1 Tracleer is the First of the Endothelin Receptor Antagonists and a Major Advance in the Treatment of Pulmonary Arterial Hypertension
9.2.2 European Approval for Digital Ulcers In Patients With Systemic Sclerosis And Ongoing Digital Ulcer Disease
9.2.3 Trials for Congestive Heart Failure
9.3 Tekturna/Rasilez - The Trailblazer of the New Renin Inhibitor Class
9.3.1 Novartis Will Gain a Significant First-Mover Advantage With Aliskiren
9.3.2 Approval and Launch of Aliskiren in the US
9.3.3 EU Approval for Aliskiren in June 2007
9.4 Other Agents Will Have an Increasing Presence in This Group
10. An Analysis of Factors That Influence the Hypertension Market
10.1 SWOT Analysis of the Hypertension Market
10.2 An Expanding Patient Population Constitutes the Principal Driver in the Hypertension Market
10.3 The Hypertension Market Has Opportunities for Continuing Growth
10.4 Changes in Blood Pressure Treatment Guidelines - Can Both Patients and Drug Companies Benefit?
10.5 Advances in Technology Are Likely to Bring Benefits to the Market
10.6 The Principal Restraints in the Hypertension Market
10.7 To What Extent is the Hypertension Market Threatened by Generic Substitutes?
10.8 What Unmet Market Needs Exist in the Hypertension Market? - Experts Provide Their Views
10.8.1 Resistant Hypertension Constitutes a Major Limitation of Present Treatments
10.8.2 Important Patient Sub-Populations: Potential For Companies To Increase Market Leverage Through Product Differentiation
10.9 Comparative Studies - A Two Edged Sword
11. A Geographical Breakdown of the World Hypertension Market
11.1 The US Will Lead a High Revenue Global Market in 2010
11.2 The Prevalence of Hypertension Worldwide - Many Hypertensive People Currently Untreated or Under-treated
11.3 There is An Urgent Requirement To Expand the Treatment of Hypertension on a Global Scale
12. Pipeline Developments in Hypertension
12.1 Submitted and Approved Agents for Hypertension
12.1.1 Tekturna HCT
12.1.2 Cleviprex
12.1.3 CS 8663
12.2 Phase III Developments for Hypertension
12.2.1 Coreg CR Combination
12.2.2 CS 866AZ
12.2.3 Actelion 1
12.2.4 Darusentan
12.3 Phase II Developments for Hypertension
12.3.1 Ilepatril
12.3.2 TAK 491
12.3.3 PST 2238
12.3.4 PF 489791
12.3.5 Fimasartan
12.3.6 SPP 635
12.3.7 Daglutril
12.3.8 NCX 4016
12.3.9 SLx 2101
12.3.10 Protherics’ Immunotherapeutic Vaccine
12.3.11 TBC 3711
12.3.12 SB 221
12.3.13 CYT006-AngQb
12.3.14 MC-4232
12.3.15 MK 0736
12.3.16 MC-4262 from Medicure
12.4 Early Stage Developments in Hypertension
12.4.1 MC 4262
12.4.2 Actelion’s Renin Inhibitor Development with Merck & Co
12.4.3 SPP 1148
12.4.4 MC-1
12.5 The Renin Inhibitors May Be One of the Few Other Drugs To Challenge The Angiotensin II Inhibitors During The Forecast Period
13 Conclusions: Hypertension Constitutes a Large Drugs Market with Scope for Expansion Worldwide List of Figures
13.1 Hypertension is a Serious, Growing Problem Worldwide
13.2 Hypertension Constitutes a High Revenue Market with Continuing Growth Potential
13.3 Hypertension Drugs will Achieve High Revenues in all the Major Geographical Markets from 2005-2010
13.4 The Pipeline for Hypertension Drugs is Strong
13.5 Continuing Public and Private Sector Investment is Required
List of Tables
Table 2.1, Categories for Blood Pressure in Adults
Table 2.2, Leading Beta-Blockers to Treat Hypertension
Table 2.3, Leading ACE Inhibitors to Treat Hypertension
Table 2.4, Leading Calcium Channel Blockers to Treat Hypertension
Table 2.5, Leading Angiotensin II Blockers to Treat Hypertension
Table 2.6, Leading Alpha Blockers to Treat Hypertension
Table 3.1, Blockbuster Drugs in the World Hypertension Market, 2006
Table 3.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
Table 3.3, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
Table 3.4, World Market Revenue ($m), 6-Year CAGR (%) and Market Share (%) for Hypertension Drugs by Class, 2006 & 2012 Table 3.5, World Market Revenue ($m), 2012, and CAGR (%) for Hypertension Drugs by Class, 2012-2023
Table 3.6, World Market Revenue ($m) and Change (%), 2006 and 2012
Table 4.1, World Revenues ($m) for Angiotensin II Blockers, 2006-2012
Table 4.2, World Revenues ($m) for Angiotensin II Blockers, 2013-2023
Table 4.3, Patent Expiry for Leading Angiotensin II Blockers, 2007
Table 4.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Angiotensin II Blockers, 2006 & 2012 Table 4.5, World Market Revenue ($m), 2012, and CAGR (%) for Angiotensin II Blockers, 2012-2023
Table 5.1, World Revenues ($m) for Calcium Channel Blockers, 2006-2012
Table 5.2, World Revenues ($m) for the Calcium Channel Blockers, 2013-2023
Table 5.3, Patent Expiry for Calcium Channel Blockers to Treat Hypertension
Table 5.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Calcium Channel Blockers, 2006 & 2012 Table 5.5, World Market Revenue ($m), 2012, and CAGR (%) for Calcium Channel Blockers, 2012-2023
Table 6.1, World Revenues ($m) for Beta Blockers, 2006-2012
Table 6.2, World Revenues ($m) for the Beta Blockers, 2013-2023
Table 6.3, Patent Expiry for Beta-Blockers to Treat Hypertension
Table 6.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Beta Blockers, 2006 & 2012
Table 6.5, World Market Revenue ($m), 2012, and CAGR (%) for Beta Blockers, 2012-2023
Table 7.1, World Revenues ($m) for ACE Inhibitors, 2006-2012
Table 7.2, World Revenues ($m) for ACE Inhibitors, 2013-2023
Table 7.3, Patent Expiry for ACE Inhibitors to Treat Hypertension
Table 7.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for ACE Inhibitors, 2006 & 2012
Table 7.5, World Market Revenue ($m), 2012, and CAGR (%) for ACE Inhibitors, 2012-2023
Table 8.1, World Revenues ($m) for Alpha Blockers, 2006-2012 Table 8.2, World Revenues ($m) for Alpha Blockers, 2013-2023 Table 8.3, Patent Expiry for Alpha Blockers to Treat Hypertension
Table 8.4, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Alpha Blockers, 2006 & 2012
Table 8.5, World Market Revenue ($m), 2012, and CAGR (%) for Alpha Blockers, 2012-2023
Table 9.1, World Revenues ($m) for Other Agents, 2006-2012
Table 9.2, World Revenues ($m) for Other Agents, 2013-2023
Table 9.3, World Market Revenue ($m) and Market Share (%) and 6-Year CAGR (%) for Other Agents, 2006 & 2012
Table 9.4, World Market Revenue ($m), 2012, and CAGR (%) for Other Agents, 2012-2023
Table 10.1, Leading Anti-hypertensive Drugs That Face The Greatest Threat From Generic Competition, 2005
Table 11.1, Estimated Hypertensive Patient Populations by Country, 2004
Table 11.2, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012
Table 13.1, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2012
Table 13.2, World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2013-2023
Table 13.3, Estimated Total Sales ($m) For Hypertension Drugs by Leading National Market, 2006 and 2012
List of Figures
Figure 3.1 World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
Figure 3.2 World Revenues ($m) for the Leading Hypertension Drugs, by Class, 2006-2023
Figure 3.3 World Market Share (%) for Hypertension by Class, 2006
Figure 3.4, World Market Share (%) for Hypertension by Class, 2012
Figure 3.5, Changes ($m) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
Figure 3.6, Changes (%) in World Revenues for the Classes of Hypertension Drugs, 2006-2012
Figure 4.1, Total World Revenues ($m) for Angiotensin II Blockers, 2006-2023
Figure 4.2, World Revenues ($m) for the Angiotensin II Blockers by Leading Product, 2006-2023
Figure 4.3, World Market Share (%) for Angiotensin II Blockers, 2006
Figure 4.4, World Market Share (%) for the Angiotensin II Blockers, 2012
Figure 4.5, World Diovan Revenues ($m), 2006-2023
Figure 4.6, World Cozaar/Hyzaar Revenues ($m), 2006-2023
Figure 4.7, World Avapro/Aprovel and Avalide Revenues ($m), 2006-2023
Figure 4.8, World Blopress Revenues ($m), 2006-2023
Figure 4.9, World Micardis Revenues ($m), 2006-2023
Figure 4.10, World Benicar/Olmetec Revenues ($m), 2006-2023
Figure 4.11, World Exforge Revenues ($m), 2006-2023
Figure 4.12, World Revenues ($m) for Other Angiotensin II Blockers, 2006-2023
Figure 5.1, Total World Revenues ($m) for Calcium Blockers, 2006-2023
Figure 5.2, World Revenues ($m) for the Calcium Blockers by Leading Product, 2006-2023
Figure 5.3, World Market Share (%) for Calcium Blockers, 2006
Figure 5.4, World Market Share (%) for the Calcium Blockers, 2012
Figure 5.5, World Norvasc Revenues ($m), 2006-2023
Figure 5.6, World Lotrel Revenues ($m), 2006-2023
Figure 5.7, World Adalat Revenues ($m), 2006-2023
Figure 5.8, World Amlodin Revenues ($m), 2006-2023
Figure 5.9, World Revenues for Other Calcium Blockers ($m), 2006-2023
Figure 6.1, Total World Revenues ($m) for Beta Blockers, 2006-2023
Figure 6.2, World Revenues ($m) for the Beta Blockers by Leading Product, 2006-2023
Figure 6.3, World Market Share (%) for Beta Blockers, 2006
Figure 6.4, World Market Share (%) for the Beta Blockers, 2012
Figure 6.5, World Toprol-XL/Seloken Revenues ($m), 2006-2023
Figure 6.6, World Coreg Revenues ($m), 2006-2023
Figure 6.7, World Concor/Bisoprolol Revenues ($m), 2006-2023
Figure 6.8, World Revenues ($m) for Other Beta Blockers, 2006-2023
Figure 7.1, Total World Revenues ($m) for ACE Inhibitors, 2006-2023
Figure 7.2, World Revenues ($m) for the ACE Inhibitors by Leading Product, 2006-2023
Figure 7.3, World Market Share (%) for ACE Inhibitors, 2006
Figure 7.4, World Market Share (%) for the ACE Inhibitors, 2012
Figure 7.5, World Delix/Tritace Revenues ($m), 2006-2023
Figure 7.6, World Altace Revenues ($m), 2006-2023
Figure 7.7, World Vasotec/Vaseretic Revenues ($m), 2006-2023
Figure 7.8, World Revenues ($m) for Other ACE Inhibitors, 2006-2023
Figure 8.1, Total World Revenues ($m) for Alpha Blockers, 2006-2023
Figure 8.2, World Revenues ($m) for the Alpha Blockers by Leading Product, 2006-2023
Figure 8.3, World Market Share (%) for Alpha Blockers, 2006
Figure 8.4, World Market Share (%) for the Alpha Blockers, 2012
Figure 8.5, World Cardura Revenues ($m), 2006-2023
Figure 8.6, World Revenues ($m) for Other Alpha Blockers, 2006-2023
Figure 9.1, Total World Revenues ($m) for Other Anti-Hypertensives, 2006-2023
Figure 9.2, World Revenues ($m) for Other Anti-Hypertensives by Leading Product, 2006-2023
Figure 9.3, World Market Share (%) for Other Anti-Hypertensives, 2006
Figure 9.4, World Market Share (%) for Other Anti-Hypertensives, 2012
Figure 9.5, World Tracleer Revenues ($m), 2006-2023
Figure 9.6, World Tekturna/Rasilez Revenues ($m), 2006-2023
Figure 9.7, World Revenues ($m) for Other Agents in This Group, 2006-2023
Figure 10.1, A SWOT Chart for the Hypertension Market, 2005-2010
Figure 11.1, Estimated Hypertensive Populations by Country, 2004
Figure 11.2, Revenues ($m) for Hypertension Drugs by Country, 2006
Figure 11.3, Revenues ($m) for Hypertension Drugs by Country, 2012

Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb market hypertension antihypertensive 2007 sales inhibitors anti share world ace

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.